New antibody drug targets artery inflammation in heart disease trial

NCT ID NCT06572267

Recruiting now Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether meplazumab, an antibody given by IV, can reduce inflammation and fatty buildup in the arteries of people with coronary artery disease. The study involves 18 participants and will compare three different doses to a placebo. It is an early, exploratory study focused on safety and finding the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Meplazumab (a lab-made antibody given by IV infusion)
What this could lead to: If it works, this could point toward a new way to reduce artery inflammation and slow plaque buildup in people with coronary artery disease.
What could go wrong: This is a very small, early-phase trial with only 18 participants, so results may not apply widely. The drug's long-term safety and effectiveness are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ling Tao
RECRUITING

Xi'an, Shannxi, 710032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.